Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06892639 · ClinicalTrials.gov registry record · Phase 3
Evaluation of D-Fi for the Treatment of Wounds Due to DEB
A Phase 3 study of Dystrophic Epidermolysis Bullosa, sponsored by Castle Creek Biosciences.
- Active
- Registry status
- Phase 3
- Development phase
- 32
- Enrollment target
- 4
- Study locations
NCT06892639: Active Phase 3 study of Dystrophic Epidermolysis Bullosa, sponsored by Castle Creek Biosciences.
NCT06892639 is a Phase 3 study of Dystrophic Epidermolysis Bullosa that is active but no longer recruiting, run by Castle Creek Biosciences. The registered enrollment target is 32 participants, above the 16-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (100% higher). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06892639, a Phase 3 study of Dystrophic Epidermolysis Bullosa, is active but no longer recruiting, sponsored by Castle Creek Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 32 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Conditions Studied
Interventions
- BIOLOGICAL D-Fi
Study Locations (4)
California
- Stanford University School of Medicine, Dermatology - Redwood City
- Mission Dermatology - Santa Margarita
Colorado
- Children's Hospital Colorado - Aurora
Massachusetts
- University of Massachusetts - Worcester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2025-03-27 |
| Est. Completion | 2042-02 |
| Phase | Phase 3 |
What the registry record for NCT06892639 still lists
NCT06892639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, above the 16-participant average among 7 other Dystrophic Epidermolysis Bullosa trials with a reported enrollment target (100% higher).
The record links to 1 condition, with Dystrophic Epidermolysis Bullosa appearing as the primary indexed condition, and to 1 intervention - of which D-Fi is the first listed.
NCT06892639 reports a single indexed study location in California, Colorado, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06892639 about?
NCT06892639 is a clinical study titled "Evaluation of D-Fi for the Treatment of Wounds Due to DEB". The purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
What is the current status of trial NCT06892639?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 32 participants. The study started on 2025-03-27. Estimated completion is 2042-02.
What conditions does trial NCT06892639 study?
This clinical trial studies the following conditions: Dystrophic Epidermolysis Bullosa.
What interventions are being tested in trial NCT06892639?
The interventions under investigation include: D-Fi (BIOLOGICAL).
Who is sponsoring clinical trial NCT06892639?
This trial is sponsored by Castle Creek Biosciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06892639 being conducted?
This trial has 4 study locations across California, Colorado, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dystrophic Epidermolysis Bullosa
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 3
-
Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
Long-Term Follow-up Protocol
RECRUITING
-
Study to Evaluate Safety and Efficacy of ALLO-ASC-SHEET in Subjects With Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 2
-
MSC EVs in Dystrophic Epidermolysis Bullosa
RECRUITING · Phase 1
-
A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI